Sonder is proud to introduce Spravato (esketamine), a groundbreaking treatment option for those who haven’t found relief through traditional antidepressants.
Are you or someone you care about struggling with treatment-resistant depression?
We have exciting news to share!
Sonder is proud to introduce Spravato (esketamine), a groundbreaking treatment option for those who haven’t found relief through traditional antidepressants.
Read on for answers to the most frequently asked questions about Spravato (Esketamine) for Treatment-Resistant Depression:
What is Spravato (esketamine) for Treatment-Resistant Depression?
Spravato is an innovative, FDA-approved nasal spray specifically designed for individuals battling treatment-resistant depression (TRD). Unlike conventional antidepressants, Spravato targets glutamate receptors in the brain, offering a unique approach that may provide rapid relief from depression symptoms, often within one to two weeks.
Who is a good candidate for Spravato?
Spravato is especially beneficial for adults with Major Depressive Disorder (MDD) who have not responded to at least two different antidepressant medications. If you meet the following criteria, Spravato might be the right fit for you:
- Diagnosed with MDD.
- Have tried and not responded to at least two different antidepressant medications.
- Are open to a treatment plan that includes both Spravato and an oral antidepressant.
Does Spravato really work?
Yes! Clinical studies have demonstrated Spravato’s effectiveness in reducing depression symptoms. Key findings include:
- Over 50% of patients experience a significant reduction in symptoms.
- Many notice improvements within the first week of treatment.
These results underscore Spravato’s potential to offer rapid and significant relief for those with chronic depression.
What does the treatment process look like?
At Sonder, we’ve streamlined the process to make your experience as smooth and supportive as possible:
- Initial Assessment: Begin with a phone consultation with Mitch, our Spravato Coordinator. Mitch will gather information and answer your questions. We’ll then schedule an intake with a Spravato provider.
- Administration: Spravato is administered as a nasal spray in our comfortable outpatient setting. Each session lasts about 1 to 2 hours, with brief post-treatment monitoring for safety.
- Treatment Schedule: Initially, treatments are administered twice a week for the first month. This is typically followed by weekly sessions, and then transitioning to monthly as needed.
Are there any side effects of Spravato (esketamine) for Treatment-Resistant Depression?
Most patients tolerate Spravato well, but possible side effects can include:
- Dissociation or feeling disconnected
- Dizziness
- Nausea
- Headache
- Increased blood pressure
These side effects are generally mild and temporary. We closely monitor your experience to address any issues promptly.
Is Spravato covered by insurance?
Yes! Most insurance plans cover Spravato, including both the medication and its administration. At Sonder, we perform a benefits investigation and provide a cost estimate before starting treatment. We also offer financing options and can assist with Spravato’s financial assistance program for eligible patients.
Is there a long waiting list?
Good news: Spravato services are currently available at our Minnetonka location, and we have immediate availability for new patients!
How do I get started with Spravato (esketamine) for Treatment-Resistant Depression?
Getting started with Spravato is simple:
Fill out the form at the bottom of this page and Mitch, our Spravato Coordinator, will contact you within one business day.
You can also reach us via email at spravato@sonderwellness.com or call 952-999-6097, option 1.
We’re excited to offer this advanced treatment option and look forward to supporting you on your journey to better mental health!
Interested in learning more about Spravato (esketamine) for Treatment-Resistant Depression?